Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on May 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). UroGen reported financial results for the quarter ended March 31, 2026.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- UroGen reported financial results for the quarter ended March 31, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
- Results disclosure enables investors to assess quarterly performance and financial condition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.